Lexicon Short Term Debt from 2010 to 2025

LXRX Stock  USD 0.36  0.01  3.86%   
Lexicon Pharmaceuticals Short Term Debt yearly trend continues to be fairly stable with very little volatility. Short Term Debt will likely drop to about 1.1 M in 2025. During the period from 2010 to 2025, Lexicon Pharmaceuticals Short Term Debt regression line of annual values had r-squared of  0.23 and arithmetic mean of  7,526,391. View All Fundamentals
 
Short Term Debt  
First Reported
2000-03-31
Previous Quarter
1.3 M
Current Value
1.2 M
Quarterly Volatility
M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lexicon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexicon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 507.3 K, Interest Expense of 16.4 M or Total Revenue of 45.7 M, as well as many indicators such as Price To Sales Ratio of 7.22, Dividend Yield of 0.0 or PTB Ratio of 1.54. Lexicon financial statements analysis is a perfect complement when working with Lexicon Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Lexicon Pharmaceuticals Correlation against competitors.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Latest Lexicon Pharmaceuticals' Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Lexicon Pharmaceuticals over the last few years. It is Lexicon Pharmaceuticals' Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexicon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Slightly volatile
   Short Term Debt   
       Timeline  

Lexicon Short Term Debt Regression Statistics

Arithmetic Mean7,526,391
Geometric Mean3,824,378
Coefficient Of Variation106.30
Mean Deviation6,920,158
Median2,015,000
Standard Deviation8,000,184
Sample Variance64T
Range23.8M
R-Value(0.48)
Mean Square Error52.6T
R-Squared0.23
Significance0.06
Slope(810,142)
Total Sum of Squares960T

Lexicon Short Term Debt History

20251.1 M
20241.2 M
20221.3 M
20211.1 M
202012.2 M
201911 M
20181.1 M

About Lexicon Pharmaceuticals Financial Statements

Lexicon Pharmaceuticals investors use historical fundamental indicators, such as Lexicon Pharmaceuticals' Short Term Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexicon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short Term Debt1.2 M1.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.